CURE’s thyroid cancer page is an extensive resource of cancer information featuring the latest thyroid cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on thyroid cancer.
January 31st 2025
From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.
September 27th 2024
LOXO-292 Granted Breakthrough Designation for Thyroid Cancer
October 15th 2018The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
LOXO-292 Granted Breakthrough Therapy Designation for Lung and Thyroid Cancer
September 5th 2018The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
FDA Approves Combination for Rare Thyroid Cancer Type
May 4th 2018The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.
Thyroid Cancer Survivors Diagnosed Before 40 At Higher Risk For Aging-Related Disease
December 31st 2017Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
Higher Risk of Thyroid Cancer Among Those With Breast Cancer History
March 11th 2015According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.
Lenvatinib Approval for Thyroid Cancer 'Likely" as FDA Decision Date Nears
February 12th 2015With a deadline of April 14, the FDA will soon make its final approval decision on lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Several Cancer Therapies Up for FDA Review in 2015
January 13th 2015The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.